Background/Aims: MicroRNAs (miRNAs) have been consistently demonstrated to be involved in colorectal cancer as either tumour oncogenes or tumour suppressors. However, the detailed role of miR-520a-3p in colorectal cancer remains poorly understood. Methods: Quantitative RT-PCR and western blotting assays were used to measure miR-520a-3p and EGFR expression levels in colorectal cancer tissues, respectively. Luciferase reporter assay was employed to validate the direct targeting of EGFR by miR-520a-3p. Cell migration, apoptosis and cell cycle assays were performed to analyse the biological functions of miR-520a-3p and EGFR in colorectal cancer cells. In vivo experiment was performed to analyse the effects of miR-520a-3p and EGFR on the growth of colorectal cancer xenografts in mice. Results: In this study, we found that miR-520a-3p was most likely to target the EGFR 3'-UTR, which was experimentally validated. In addition, we investigated the biological effects of EGFR inhibition by miR-520a-3p both in vitro and in vivo and found that miR-520a-3p could suppress cell migration, promote apoptosis, lead to colorectal cancer cell cycle arrest at the G0/G1 phase, and decelerate tumour growth in xenograft mice, potentially by targeting EGFR. Conclusions: This study highlights a tumour suppressor role for miR-520a-3p in colorectal cancer via the regulation of EGFR expression. Thus, miR-520a-3p may be a novel molecular therapeutic target for colorectal cancer.
Introduction
Colorectal cancer is one of the most common malignancies worldwide. Approximately 1.2 million patients worldwide have been diagnosed with colorectal cancer, and more than 600,000 patients have died directly or indirectly because of colorectal cancer [1] . In recent years, with continuous improvements in living standards, eating habits and diet, population ageing, morbidity and mortality rates of colorectal cancer have also been on the rise. because biomarkers have begun to play an increasingly important role in the detection and management of patients with colorectal cancer [2] . The human epidermal growth factor receptor (EGFR) protein regulates cancer cell growth and apoptosis and has been validated as a relevant therapeutic target in several human cancers, including colorectal cancer [3, 4] . The accumulation of EGFR in colorectal cancer has been widely reported [5, 6] . In recent years, new anticancer drugs that target EGFR have been developed and have demonstrated of such drugs are cetuximab and panitumumab [7] [8] [9] . However, only a small percentage of colorectal cancer patients are sensitive to anti-EGFR therapy, and even those who initially respond to therapy are limited by the emergence of secondary EGFR mutations or other mutations in colorectal cancer patients are urgently needed.
MicroRNAs (miRNAs) are a class of endogenous noncoding RNAs that are typically 22 nucleotides in length and function primarily by targeting the 3'-untranslated region (3'-UTR) mRNA degradation [12] . Through these post-transcriptional gene regulation mechanisms, miRNAs regulate a wide range of biological processes, including cell apoptosis and differentiation, migration, apoptosis, development and metabolism [13] [14] [15] . Accumulating evidence has shown aberrant miR-520 expression in tissue samples from with many types of human malignant tumours [16] . The miR-520 family acts as a tumour suppressor in many human cancers. For example, miR-520d-5p, a member of the miR-520 family, has been reported to act as anti-onco-miRNAs in colorectal cancer [17] .
In this study, we showed that miR-520a-3p expression was negatively associated with EGFR in colorectal cancer tissues and cell lines. By using gain-of-function and loss-ofin vitro and in vivo therapeutic implications for the cure of colorectal cancer.
Materials and Methods

Tissue samples
Hospital of Nanjing University Medical School (Nanjing, China) were enrolled in this study. Paired colorectal their information and samples to be used in this study, and this study was approved by the Ethics Committee of Nanjing University. The clinical features of the patients are listed in Table 1 .
GATATT
The miR-520a-3p expression was performed with TaqMan miRNA probes (Applied Biosystems). The detailed description of experimental details is given in our previous article [18] .
Target predictions
Then, miRNAs which predicted at least by two algorithms were selected and the RNAhybrid software was used to assess whether the binding of the miRNA to its target must be completely complementary and not mismatched. Finally, we refer to the relevance of miRNA and cancer and its negative correlation with the target gene selecting the appropriate miRNA for further study.
Plasmid construction and luciferase assay
The EGFR 3'-UTR sequence containing the presumed miR-520a-3p binding sites or mutated binding sites were inserted into the p-MIR-reporter plasmid (Ambion). Then, SW480 cells were seeded into 12-galactosidase expression plasmid (used as a transfection control), and scrambled ncRNA, miR-520a-3p mimic or miR-520a-3p inhibitor using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Twenty-four hours after the transfection, cells were measured by a luciferase assay kits (Promega) according to the manufacturer's protocols.
Protein extraction and Western blotting
Total protein was isolated from cells lysed with RIPA lysis buffer (Beyotime, Shanghai, China) Cruz Biotechnology) was used as the control to normalize the relative expression level of EGFR.
Cell migration assay
Cell migration assays were performed using 24-Well matrigel-coated chambers (Millipore) containing (2 × 10 4 
Cell cycle analysis Apoptosis
To induce apoptosis, cells transfected with the abovementioned RNAs or plasmids were treated with
Animal studies
Research Centre of Nanjing University (Nanjing, China). All animal experiments were approved by the group) and injected subcutaneously with 1 × 10 4 HT29 cells which infected with control lentivirus or miR520a-3p lentivirus, EGFR overexpression plasmid or co-transfected with miR-520a-3p lentivirus and EGFR were measured. Tumours were taken to perform western blot analysis and qRT-PCR analyses and tumour section slides were subjected to Haematoxylin and Eosin (H&E) staining or immunohistochemical (IHC).
Statistical analysis
Results
Up-regulation of EGFR protein in human colorectal cancer tissues
In agreement with previous studies, EGFR was found to be consistently overexpressed in human colorectal cancer tissues. As shown in Fig. 1A and 1B, EGFR protein levels were pairs of colorectal cancer tissues and adjacent normal tissues. Moreover, we analysed EGFR mRNA expression in the same colorectal cancer tissue pairs by quantitative RT-PCR (qRT-PCR). EGFR mRNA expression was slightly increased in colorectal cancer tissues compared to adjacent normal tissues (Fig. 1C ). This disparity between EGFR protein and mRNA level in colorectal cancer tissues strongly suggests that EGFR protein level may be involved in a post-transcriptional mechanism.
MiRNAs are crucial regulators in colorectal cancer. Multiple target prediction programs were applied to identify potential miRNAs that target EGFR. Based on the species conservation and the minimum free energy (MFE) of its binding sites as well as its cancer correlations, miR-520a-3p was highlighted for further investigation. Figure 2A illustrated the predicted interaction between miR-520a-3p and the target site in the EGFR 3'-UTR and the minimum To investigated whether miR-520a-3p expression levels are inversely correlated with EGFR expression in colorectal cancer tissues, same 8 pairs of colorectal cancer tissues and adjacent normal tissues were used to measure the expression levels of miR-520a-3p and the Pearson's correlation scatter plot of the fold change of miR-520a-3p and EGFR protein expression in human 2C) and an irregular alteration was observed between the miR-520a-3p and EGFR mRNA we analysed 200 pairs of colorectal cancer tissue samples from TGCA database to perform the correlation of miR-520a and EGFR mRNA by using Pearson's correlation scatter plots. As shown in Fig. 9 , miR-520a-3p levels were consistently lower in CRC tissues, however there is irregular alteration between miR-520a and EGFR mRNA.
MiR-520a-3p directly targets EGFR at the posttranscriptional level
regulated by miR-520a-3p through interactions at the 3'-UTR. The EGFR 3'-UTR sequence containing the presumed miR-520a-3p binding sites was cloned at a downstream position 3p inhibitor or negative control RNAs (ncRNAs). As expected, the miR-520a-3p mimic decreased the luciferase activity to 11% of the baseline reporter construct luciferase activity, whereas the miR-520a-3p inhibitor increased the luciferase activity by 2.2-fold. Meanwhile, we introduced point mutations into the seed complementary sites (the core sequence that 
MiR-520a-3 and EGFR have opposite effects on colorectal cancer cells
To investigate whether miR-520a-3p affected the tumourgenesis of colorectal cancer cells, migration and cell apoptosis assays in colorectal cancer cells was conducted. SW480 and HT29 cells were transfected with equal doses of miR-520a-3p mimic, miR-520a-3p analyse the effect of miR-520a-3p on colorectal cancer cell migration ( Fig. 4A and 4B) . The transwell assay revealed that migratory capabilities were greatly decreased in SW480 and HT29 cells that were transfected with the miR-520a-3p mimic and increased in cells that were transfected with the miR-520a-3p inhibitor. The effects of miR-520a-3p on apoptosis with the miR-520a-3p inhibitor had the opposite effect on colorectal cancer cell apoptosis To investigate whether miR-520a-3p and EGFR expression can affect the cell cycle, miR520a-3p was overexpressed or knocked down in SW480 and HT29 cells, and the cells were in the fraction of cells in S phase (Fig. 5A , 5B and 5E). In contrast, knockdown of miR-520a- Because a single miRNA are generally thought to target multiple genes, it is essential to identify whether it is due to miR-520a-3p-mediated EGFR inhibition. The precise effect of the miR-520a-3p-EGFR axis on colorectal cancer cell apoptosis and migration was performed using a siRNA and an overexpression plasmid to down-regulate or up-regulate and HT29 cells. Comparison with the fact that overexpression of EGFR had the opposite EGFR overexpression plasmid. Transfecting cells with EGFR siRNAs markedly increased phases ( Fig. 7G and 7H) . Thus, miR-520a-3p and EGFR have opposite biological functions in colorectal cancer cells.
To investigate whether the regulation of cell apoptosis, migration and cell cycle by miR520a-3p is an EGFR-dependent process, we co-transfected SW480 and HT29 cells with the EGFR overexpression plasmid and miR-520a-3p mimic. As we expected, cells co-transfected with the miR-520a-3p mimic and EGFR overexpression plasmid showed dramatically higher miR-520a-3p mimic. Thus, restoration of EGFR expression can rescue the miR-520a-3p-induced suppression of cell migration as well as miR-520a-3p-induced cell apoptosis and mechanism by which miR-520a-3p exerts its tumour suppressor functions.
MiR-520a-3p and EGFR affect colorectal cancer growth in vivo
of colorectal cancer xenografts in mice, HT29 cells which infected with a miR-520a-3p lentivirus, transfected cells with an EGFR overexpression plasmid, or co-transfected cells reporter containing either wild-type (WT) or mutant EGFR 3'-UTR was co-transfected into SW480 cells with a control mimic, miR-372 mimic, control inhibitor or miR-372 inhibitor. For comparison, luciferase activity in the ncRNA-transfected cells was set at 1. The y-axis shows arbitrary units representing the relative luciferase activity. (B) Western blot analysis of the expression levels of EGFR protein in SW480 cells transfected with equal dose of control mimic, miR-372 mimic, control inhibitor or with a miR-520a-3p overexpression lentivirus and an EGFR overexpression plasmid were subcutaneously implanted into nude mice. Consistent with the results obtained in the in vitro by miR-520a-3p and tumour growth in the EGFR-overexpressing group was dramatically promoted ( Fig. 6A and 6B) . Additionally, EGFR overexpression rescued the suppressive effects of miR-520a-3p, suggesting that miR-520a-3p suppresses tumour growth by silencing EGFR, however overexpression of EGFR does not completely abolish the suppressive tumour growth induced by miR-520a-3p ( Fig. 6A and 6B ). Next, we isolated total RNA and protein from the xenograft tumours and analysed. Tumours from the miR-520a-3p-overexpression tumours from the control group (Fig. 6C) . Likewise, western blotting revealed a repressed EGFR expression in miR-520a-3p-overexpression group, whereas tumours from the suggesting that EGFR overexpression could rescue EGFR suppression caused by miR-520a-3p. Additionally, we performed H&E staining or immunohistochemical staining of xenograft group, whereas more mitosis in the EGFR-overexpressing group. Xenograft tumour tissues with both miR-520a-3p and EGFR displayed more cell mitosis compared to xenografts tumour tissues implanted with miR-520a-3p lentivirus (Fig. 6F) . Immunohistochemical staining also showed lower EGFR protein levels in tumour tissues from miR-520a-3p-overexpressing group, whereas tumours from the EGFR-overexpressing group revealed increased EGFR protein levels ( Fig. 6F and 6G) . Finally, the proliferative activity of tumour cells was assessed via Ki-67 immunohistochemical staining. Ki-67 indexes was decreased in the miR-520a-3p lentivirus-treated cells implanted group and was increased in the plasmid-transfected cells implanted group (Fig. 6F and 6H) . Furthermore, EGFR overexpression rescued the antiproliferative achieves of miR-520a-3p overexpression and overexpression of EGFR does not completely abolish the anti-proliferative achieves induced by miR-520a-3p ( Fig. 6F and 6H ).
cancer tumourgenesis is achieved by targeting EGFR.
Discussion
In recent years, it was found that miRNAs and tumour occurrence as well as development are closely related [19] [20] [21] . Compared with normal tissues, the expression of miRNA in genes and proto-oncogenes and plays a dual role in tumourgenesis and development [22, 23] . MiRNAs can function as an oncogene, and the targeting of tumour suppressor genes by these oncogenic miRNAs provides favourable conditions for tumour growth, metastasis and and the targeting of oncogenes by these miRNAs can contribute to tumour apoptosis, . For example, aberrantly activated miRNAs can be silenced using antagomirs, and re-expression of miRNAs that are lost in cancers can be achieved by the induction of miRNA mimics [18, 33, 34] . It has been found that aberrant expression of the miR-520 family occurs in malignant tumours, and transcripts in this cancer. As a member of the miR-520 family, miR-520d-5p suppresses tumour growth and metastasis in colorectal cancer by targeting CTHRC1 [17] . A recent study showed that miR520g inhibits proliferation and induces apoptosis in oesophageal squamous cell cancer by promote tumour invasion as well as metastasis [36] . Interestingly, a similar phenomenon was also found in prostate cancer where miR-520c could enhance the invasion of prostate suppress migration and promote apoptosis in vitro and suppress tumour growth in vivo.
A large number of studies have shown that EGFR signalling plays an important role in the progression of colorectal cancer [38] . Overexpression of EGFR is observed in approximately 65% to 70% of colorectal cancer patients, and it is closely correlated with clinical stage, serosa invasion and lymph node involvement, indicating that EGFR-positive tumours may have a stronger ability to proliferate and invade and that EGFR can be used as an indicator of the progress and prognosis of colorectal cancer [5, 39, 40] . Therefore, EGFR is an important target for the inhibition of tumour growth. Currently, there are two main classes of drugs domain of EGFR, such as cetuximab, panitumumab monoclonal antibody, etc., which binds that can enter the cell and directly bind the EGFR intracellular tyrosine kinase region, which interferes with the binding of ATP and inhibits tyrosine kinase activity to prevent auto phosphorylation, thus blocking EGFR pathway signal transduction [43, 44] . However, many patients who initially respond to EGFR-targeted treatment eventually develop drug resistance that may be due to secondary EGFR mutations or other resistance mechanisms [10, 45] . Hence, future studies should focus on the development of new drugs to overcome and prevent resistance [46] . Considering that miR-520a-3p is an upstream regulator of EGFR, it may be possible to up-regulate miR-520a-3p inhibit EGFR expression in vivo. The reexpression of miRNAs that are lost in cancers is a novel therapeutic strategy for cancers, and transfection or viral delivery methods, have demonstrated the potential utilities of miRNAs as therapeutic molecules in the treatment of human cancers. Future research is required to characterize the feasibility of targeting miR-520a-3p for colorectal cancer therapy and develop simple and cost-effective manipulation methods.
cell migration, the acceleration of cell apoptosis, and cell cycle arrest by targeting EGFR expression of miR-520a-3p and increased expression of EGFR in human colorectal cancer 3p have opposite biological functions in vivo. Thus, the miR-520a-3p-EGFR axis is a novel
